Q-omics provides the consensus-scored TRPM1 profile across patient tissues and cancer cell-line models. TRPM1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRPM1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, TRPM1 RNA expression shows 12,658 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, LUAD, and UVM as cancer lineages where TRPM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM1 survival associations across molecular data types. TRPM1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM1 RNA expression–survival associations across cancer types. High TRPM1 expression shows unfavorable associations in SKCM, BLCA, SCLC and LGG, but favorable associations in LUSC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRPM1 RNA expression.
This table summarizes TRPM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRPM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM1 shows lower tumor expression in LUAD, KICH, KIRP, KIRC and BRCA and higher tumor expression in LIHC. The LUAD box plot shows higher TRPM1 RNA expression in normal versus tumor tissue (log2 FC = −0.141, t-test p < 0.001).
This table shows molecular features associated with TRPM1 in patient tissues and cancer cell lines. In patient samples, TRPM1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
